|Articles|March 1, 2002
- Applied Clinical Trials-03-01-2002
Selecting Sites and Investigators
The system is an important part of the selection equation in CEE nations where sponsors must contract with institutions rather than investigators. Examples from Hungary offer guidelines for improving selection SOPs.
Advertisement
Articles in this issue
over 24 years ago
Consider Geography When Choosing Investigative Sitesover 24 years ago
Meet the Editorial Advisory Board Francis Crawleyover 24 years ago
9th ACT European Summitover 24 years ago
Letters to the Editorover 24 years ago
Safety and Risk Assessment Gain Importanceover 24 years ago
Transporting Clinical Trial Samplesover 24 years ago
Forward to 2004 or Back to 1984?Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy
2
ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion
3
Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial
4
Bringing the Voice of Clinical Practice and Patients into Drug Development
5